Emerald Advisers LLC Has $36.70 Million Stake in Mirum Pharmaceuticals, Inc. $MIRM

Emerald Advisers LLC boosted its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 8.2% during the 1st quarter, HoldingsChannel reports. The firm owned 397,263 shares of the company’s stock after buying an additional 30,129 shares during the quarter. Mirum Pharmaceuticals accounts for 1.2% of Emerald Advisers LLC’s investment portfolio, making the stock its 23rd biggest holding. Emerald Advisers LLC’s holdings in Mirum Pharmaceuticals were worth $36,699,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in MIRM. Comerica Bank grew its holdings in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares in the last quarter. AQR Capital Management LLC raised its position in Mirum Pharmaceuticals by 307.3% during the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after buying an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after acquiring an additional 1,720 shares in the last quarter. Caxton Associates LLP purchased a new stake in Mirum Pharmaceuticals in the 1st quarter worth about $217,000. Finally, Empowered Funds LLC boosted its position in Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after acquiring an additional 5,120 shares during the period.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $119.04 on Tuesday. The firm has a market cap of $7.26 billion, a PE ratio of -8.75 and a beta of 0.48. The firm’s 50 day moving average price is $106.93 and its 200 day moving average price is $98.12. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. Mirum Pharmaceuticals, Inc. has a twelve month low of $50.25 and a twelve month high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The business had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. Mirum Pharmaceuticals’s revenue was up 43.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.30) earnings per share. As a group, research analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on MIRM shares. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. TD Cowen increased their price target on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. HC Wainwright reaffirmed a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Finally, Citizens Jmp upped their price objective on shares of Mirum Pharmaceuticals from $140.00 to $146.00 and gave the company a “market outperform” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $143.40.

Insider Activity

In related news, SVP Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total value of $326,520.00. Following the completion of the sale, the senior vice president owned 3,114 shares of the company’s stock, valued at approximately $373,680. The trade was a 46.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $122.25, for a total transaction of $611,250.00. Following the completion of the sale, the chief financial officer owned 42,181 shares of the company’s stock, valued at $5,156,627.25. This represents a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 65,315 shares of company stock worth $6,991,928. 8.32% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.